Mirum Pharmaceuticals (MIRM)
(Real Time Quote from BATS)
$24.60 USD
+0.05 (0.20%)
Updated May 28, 2024 11:08 AM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Brokerage Reports
Mirum Pharmaceuticals, Inc. [MIRM]
Reports for Purchase
Showing records 1 - 20 ( 99 total )
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
LIVMARLI Is Now Reimbursed in Canada For ALGS; Two Volixibat Interim Analyses Expected in 1H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Approves LIVMARLI for PFIC; Model Updates Lead to Raising Our PT to $58
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: 2024 Global Net Product Sales Guidance Set to $310-$320M, But OpEx Higher Too; Reduce PT to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q Preview and Model Updates for a 2024 Top Pick; Multiple Near-Term Catalysts Abound; Affirm Buy, $58 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary 2023 LIVMARLI Net Sales And Topline Figures Exceed Our Estimates; Expecting an Eventful 2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New Drug Prices for the New Year; We Highlight Three Recent Price Changes in Our Coverage Universe
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
LIVMARLI Was Safe in EMBARK For Biliary Atresia But Missed Primary and Key Secondary Endpoints; Moderating PT to $58
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
LIVMARLI Approved For ALGS in Italy; We Expect LIVMARLI''s PFIC FDA Approval by March 13, 2024 PDUFA Date; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for MIRM 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap: LIVMARLI Drives Significant Topline Beat; EMBARK Topline Data On Target By YE2024; PT Down to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Extended LIVMARLI sNDA Review For PFIC By Three Months; PDUFA Pushed Back to March 13, 2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mirum Appoints New CFO With Rare Disease Experience
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E